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Abstract
The phosphoinositide 3-kinase (PI3K) pathway is targeted for frequent alteration in glioblastoma (GBM) and is one of the
core GBM pathways defined by The Cancer Genome Atlas. Somatic mutations of PIK3R1 are observed in multiple tumor
types, but the tumorigenic activity of these mutations has not been demonstrated in GBM. We show here that somatic
mutations in the iSH2 domain of PIK3R1 act as oncogenic driver events. Specifically, introduction of a subset of the
mutations identified in human GBM, in the nSH2 and iSH2 domains, increases signaling through the PI3K pathway and
promotes tumorigenesis of primary normal human astrocytes in an orthotopic xenograft model. Furthermore, we show that
cells that are dependent on mutant P85a-mediated PI3K signaling exhibit increased sensitivity to a small molecule inhibitor
of AKT. Together, these results suggest that GBM patients whose tumors carry mutant PIK3R1 alleles may benefit from
treatment with inhibitors of AKT.
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Introduction
Glioblastoma (GBM) represents the most advanced and
aggressive form of glioma, with current standard of care providing
patients with a median survival of approximately 14 months [1].
Recent efforts to comprehensively characterize the genomes of
primary GBM’s have established that this disease is driven by
numerous and diverse genetic events in individual patients [2,3].
However, integrative global network analyses of these datasets
identified three core networks that were simultaneously altered in
the majority of patients [2,3]. The phosphoinositide 3-kinase
(PI3K) pathway was one of the most frequently targeted signaling
pathways in these analyses, with recurrent genetic alterations
found at multiple key nodes in the PI3K signaling cascade.
The PI3K pathway plays a critical role in regulating cellular
responses to growth factors and other environmental cues. The
Class IA PI3K heterodimer, which is composed of a P110 catalytic
subunit and a P85 regulatory subunit, is activated upon association
of the P85 subunit with upstream adaptor proteins or receptor
tyrosine kinases [4]. These interactions relieve the inhibitory
activity of P85 on P110, thus allowing P110 to phosphorylate its
lipid substrates and subsequently induce activation of downstream
effector molecules. Dominant activating mutations of PIK3CA,
encoding P110a, have been identified in a variety of tumor types,
including GBM, breast, and colon cancer, and have been shown to
promote activation of P110a despite the presence of the P85
negative regulatory subunit [2,5–7]. Here, we demonstrate that
somatic mutations in the iSH2 domain of PIK3R1, encoding P85a,
also promote GBM tumorigenesis and provide an independent
mechanism by which tumors deregulate the PI3K signaling
cascade.
Materials and Methods
Plasmids and mutagenesis
Flag-tagged human PIK3R1 was provided by Dr. J. Stommel
(National Cancer Institute, Bethesda, MD). Somatic mutations of
PIK3R1 identified in GBM by The Cancer Genome Atlas (TCGA)
were engineered into this construct using site-directed mutagen-
esis, and all resulting constructs, as well as wildtype Bovine P110a-
HA, were cloned into the pLenti4/V5-DEST lentiviral expression
vector (Invitrogen).
Cell culture and transformation assays
All cell lines were maintained in DMEM (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS; Cell Generation) and
1% penicillin/streptomycin unless otherwise noted. Anchorage-
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independent growth was assessed by seeding triplicate wells of 6-
well plates with 10,000 cells per well in 0.4% agarose on top of a
bottom layer of 0.7% agarose. Upon the formation of colonies, soft
agar plates were stained with Iodonitrotetrazolium chloride
(Sigma) and the colonies were counted manually.
In vivo tumorigenicity assays
106 cells were mixed with 50% Matrigel (Fisher) and injected
subcutaneously into flanks of 4–6 week-old NCR Nude mice
(Taconic) and monitored for tumor development. Upon appear-
ance of a tumor, weekly tumor measurements were taken and total
tumor volume was estimated by the equation l?w?h?p/6 (l= length,
w=width, h=height). Alternatively, 56105 cells were suspended
in 3 mL Hanks Balanced Salt Solution and injected intracranially
in NCR Nude mice. Briefly, mice were anaesthetized with
100 mg/kg Ketamine and 10 mg/kg Xylazine and placed in a
stereotactic frame using ear bars. A hole was bored 1 mm anterior
and 2 mm lateral to Bregma, and 3 mL of cell suspension was
injected at a depth of 3 mm using a 30G Hamilton syringe. The
incision was closed with a surgical clip and the mice were
monitored for the development of neurological or physical
symptoms. Upon onset of neurological symptoms, or upon
termination of the experiment, tumors were harvested and
processed for pathological and molecular analyses. All animal
experiments were approved by Harvard’s Institutional Animal
Care and Use Committee (IACUC) under Protocol No. 04-136.
In vitro kinase assay
293T cells were co-infected with wildtype P110a and either
wildtype or mutant P85a constructs. Cell lysates were generated
by scraping cells in ice-cold RIPA buffer (50 mM Tris-HCl
pH 7.4, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1%
SDS, Complete Mini Protease Inhibitor Cocktail [Roche], and
Phosphatase Inhibitor Cocktail Set I and II [Calbiochem]).
Immunoprecipitation of P85a complexes was performed using
anti-Flag (M2) antibody (Sigma) and expression/interaction of the
transgenes was confirmed by immunoblotting with anti-Flag and
anti-HA (Cell Signaling) antibodies. Immunoprecipitates were
assayed for PI3K activity by measuring phosphorylation of
phosphatidylinositol as described in Serunian et al [8], with minor
modifications. Briefly, immunoprecipitates were preincubated with
sonicated lipids (3 mg phosphatidylinositol and 6 mg phosphatidyl-
serine, Avanti Polar Lipids) at room temperature for 10 min.
Enzyme reactions were initiated by the addition of [c32P]ATP
(20 mCi, Perkin Elmer), ATP (40 mM final concentration) and
MgCl2 (10 mM, final concentration) in HEPES buffer (pH 7.4)
and incubated at room temperature for 20 min. The reactions
were stopped by the addition of HCl (1.3 N final concentration)
and the lipids were extracted with MeOH/CHCl3 (1:1 v/v). After
mixing vigorously to separate the phases, the organic phase was
spotted onto silica gel 60 TLC plates (Merck) that were baked at
100uC before use. Phosphorylated lipids were separated overnight
by TLC using an acetic solvent system (n-propanol-2.0M acetic
acid [65:35 v:v]). TLC plates were exposed to phosphor screens
and imaged on the Storm Phosphor Imaging System (Amersham).
Spot intensities were quantified using ImageQuant software
(Amersham). Levels of phosphorylated lipid product were
normalized to P110a protein levels, as determined by western blot.
Immunoblot analyses
Whole cell extracts were resolved using 4–12% Bis-Tris gradient
gels (Invitrogen) and transferred to PVDF membrane (Millipore)
before being probed with antibodies targeting total AKT, pAKT
(S473), total ERK1/2, pERK1/2 (T202/Y204), P110a, P110b (all
from Cell Signaling), or Vinculin (H-10, Santa Cruz).
Cytotoxicity assay
The parental interleukin-3 (IL-3)–dependent prolymphoid cell
line Ba/F3 was maintained in RPMI1640 medium containing 5%
fetal bovine serum supplemented with 5 ng/ml IL-3. Ba/F3 cells
stably expressing PIK3R1 mutants by lentiviral-based transduction
were maintained in medium without IL-3. These parental or
transfected Ba/F3 cells (56103) were seeded in 96-well plates and
treated with DMSO or MK2206 in the presence or absence of IL-
3 for 72 hours. The stock solution of MK2206 was prepared in
DMSO and used at concentrations ranging from 0.002 to 10 mM.
Cell viability was determined using Cell Titer Blue (Promega) for
mitochondrial dehydrogenase activity according to the manufac-
turer’s instruction. Two independent experiments, each in
triplicate, were performed. Dose-response curves and comparison
of fit was performed via four parameter (variable slope) non-linear
regression fit of log-normalized data in GraphPad Prism.
Statistical analyses
Differences in colony formation efficiency were assessed by
single factor ANOVA with Bonferroni correction for multiple
hypothesis testing.
Results
In addition to known oncogenic mutations in PIK3CA, recent
cancer genome sequencing efforts have identified recurrent
somatic mutations of PIK3R1 in GBM, endometrial, and colon
cancers [2,3,9,10]. Consistent with these findings, targeted
sequencing of 28 human glioma cell lines identified two lines
(LN340 and LN428) that carried variant alleles of PIK3R1 (Table
S1). Both mutations target residues (D560 and N564) that were
also reported as somatically mutated in primary GBMs [2].
As a first step to understand the functional impact of mutations
in the nSH2 or iSH2 domains of PIK3R1, 10 somatic mutations
identified in GBM by TCGA [2] were introduced into a Flag-
tagged human P85a construct. Expression of these constructs in
293T cells demonstrated that all mutant forms of P85a retained
their ability to interact with the endogenous P110a and P110b
catalytic subunits of PI3K (Fig. 1A). An in vitro kinase assay
confirmed that these mutant P85a/P110a complexes remain
catalytically active (Fig. 1B), however, three mutants exhibited
enhanced kinase activity compared to wildtype P85a.
To demonstrate pathway activation downstream of increased
P110a kinase activity, we selected the three P85a mutants
(DKRMNS560del, R574fs, and T576del) with the strongest
activities in the in vitro kinase assay for biochemical validation in
relevant cell systems. Hs683 human glioma cells and E6/E7/
hTERT-immortalized normal human astrocytes [11] were co-
infected with wildtype or mutant P85a and wildtype P110a
expression constructs to achieve stable expression, and AKT
phosphorylation was then measured as a downstream readout of
PI3K activity. As shown in Figure 1C, increased AKT phosphor-
ylation was observed in cells with enforced expression of mutant
P85a under both high and low serum culture conditions, thus
confirming that these P85a mutants were able to drive increased
signaling through the PI3K pathway independent of upstream,
serum-induced, signaling events in GBM-relevant cellular con-
texts.
To address the biological relevance of increased kinase activity
and enhanced pathway activation by mutant P85a, we next tested
their functional activities in vitro and in vivo. Here, wildtype or
Somatic Mutations of PIK3R1 Promote Gliomagenesis
PLOS ONE | www.plosone.org 2 November 2012 | Volume 7 | Issue 11 | e49466
mutant P85a constructs were introduced into Hs683 human
glioma cells and seeded in soft agar to examine their anchorage-
independent growth potential. All three mutant P85a constructs
significantly promoted colony formation in this assay of transfor-
mation potential (p,0.001; Fig. 2A). Furthermore, these mutants
enhanced tumorigenicity of human astrocytes in vivo. Specifically,
wildtype and mutant P85a constructs were stably co-expressed
with wildtype P110a in E6/E7/hTERT-immortalized but non-
transformed human astrocytes and transplanted subcutaneously in
immunocompromised mice (n = 8 injections for DKRMNS560del
subline and n= 10 injections for all other sublines). At 61 days
post-transplantation, the first analysis time point as defined by the
first animal reaching a predetermined experimental endpoint (e.g.
tumor reaching the maximum allowable size), an increase in
overall tumorigenicity by mutant P85a was readily detected
(Fig. 2B). Specifically, 40–50% of the injection sites in the three
experimental cohorts that were transplanted with cells expressing
mutant P85a had developed measurable tumors, whereas no
tumors had formed in the control parental and wildtype P85a
cohorts (Fig. 2B). The maximum tumor penetrance of mutant
P85a in this model system (62.5% for DKRMNS560del, 50% for
R574fs, and 70% for T576del) was achieved by 124 days post-
injection (Fig. 2C). Importantly, these mutant P85a-driven tumors
were verified to exhibit increased levels of pAKT, indicative of
increased flux through the PI3K pathway in these tumors (Fig. 2D).
In contrast, when the experiment was terminated at Day 300 post-
transplantation, only 30% tumor penetrance was reached in the
control parental and wildtype P85a cohorts (Fig. 2C).
Due to potential limitations of subcutaneous xenografts, we next
implanted these same cells at the orthotopic site via intracranial
injections. Astrocytes expressing mutant P85a constructs formed
tumors significantly more rapidly than astrocytes expressing
wildtype P85a (p,0.001; median latency was reduced from 148
days to 62–74 days; Fig. 3A). These tumors were also consistently
larger with numerous mitoses and evidence of necrosis, which are
pathological criteria for the diagnosis of glioblastoma (Fig. 3B, C).
However, detailed pathological review of these tumors for
evidence of invasion, morphological changes, abnormal mitoses,
or vascular changes did not identify compelling trends or
differences between tumors expressing mutant P85a relative to
Figure 1. Mutant P85a bound P110a and P110b and increased signaling through the PI3K pathway. (A) GFP, or Flag-tagged wildtype or
mutant P85a was expressed in 293T cells and whole cell lysates immunoprecipitated with anti-Flag antibody. Western blotting demonstrated that
mutant P85a constructs retained their interaction with both P110a and P110b. (B) Wildtype or mutant P85a was co-expressed in 293T cells with
wildtype P110a, and PI3K heterodimers were immunoprecipitated using anti-Flag antibody. In vitro kinase activity was assessed by measuring
phosphorylation of phosphatidylinositol, and total PIP3 signal was quantified and normalized to the total amount of P110a protein loaded in the
assay. The average activity from five independent samples is shown (6 SD). (C) Expression of mutant P85a constructs increased signaling through the
PI3K pathway. Wildtype or mutant P85a was co-expressed with wildtype P110a in Hs683 glioma cells or E6/E7/hTERT-immortalized normal human
astrocytes. The resulting cell lines were grown in the indicated concentrations of serum and western blotting was performed to assess activity of the
PI3K and MAPK pathways. Representative western blots from at least three experiments are shown. Numerical values below each pAKT panel of the
immunoblots represent quantification of the relative protein level by densitometry (normalized to AKT).
doi:10.1371/journal.pone.0049466.g001
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the smaller tumors observed in the control cohorts. Together,
these results demonstrated that mutations in the iSH2 domain of
P85a are oncogenic and capable of promoting transformation of
primary immortalized human astrocytes. Furthermore, these
experiments confirmed that somatic mutation of PIK3R1 repre-
sents an additional mechanism to deregulate PI3K signaling in
developing GBM tumors.
Given the functional significance of these mutations to the
establishment and progression of GBM, we next sought to
determine if cells expressing mutant P85a proteins are sensitive
to a small molecule inhibitor of PI3K signaling. To test this,
wildtype, DKRMNS560del, R574fs, or T576del mutant P85a
constructs were stably introduced into Ba/F3 cells, which are
dependent on exogenous Interleukin 3 (IL-3). Upon introduction
of these P85a constructs, Ba/F3 cells were cultured in the presence
or absence of IL-3 and exposed to increasing concentrations of
MK2206 (synthesized by the Translational Chemistry Core
Facility at the M.D. Anderson Cancer Center), an allosteric
AKT inhibitor currently undergoing Phase I/II clinical trials [12].
While parental cells, and cells expressing wildtype P85a, did not
exhibit differential sensitivity to AKT inhibition in the absence of
IL-3, Ba/F3 cells expressing the mutant P85a constructs exhibited
significantly increased sensitivity to MK2206 (Table 1). Addition
of IL-3 to these cells resulted in decreased sensitivity to the
inhibitor, indicating that in the absence of IL-3 the survival of
these cells was dependent on AKT activity downstream of mutant
P85a. In summary, PIK3R1 mutations in primary GBM tumor
specimens may define a subpopulation of patients who would
benefit from treatment with MK2206 or other AKT inhibitors.
Discussion
The PI3K signaling pathway plays a critical role in GBM
development and growth [13]. Loss of PTEN is one of the
signature genetic alterations of GBM, but other members of the
PI3K pathway are also frequently targeted for genetic alteration in
GBM [2,14]. Activation of PI3K signaling through the loss of
PTEN or via overexpression of AKT has also been shown to
promote GBM tumorigenesis in engineered mouse models and
primary human cell systems [15–17], thus validating the clinical
relevance of alterations in this pathway that have been found in
GBM patients [18,19].
In contrast to PIK3CA, which is characterized by the predom-
inance of somatic mutations at three ‘‘hotspot’’ residues, somatic
mutations of PIK3R1 in GBM are broadly distributed throughout
the nSH2, iSH2, and cSH2 domains of the protein [2,3,10].
Sporadic mutations were also identified outside of these three
domains, though with decreased frequency [9,10,20]. In the
current study we focused on the functional effects of three
mutations (DKRMNS560del, R574fs, and T576del) that exhibited
the highest level of P110a activity in an in vitro kinase assay. In
particular, we showed that all three mutations promote tumori-
genesis in vivo in a human GBM-relevant context. This finding is
consistent with published studies showing that these three
mutations (plus KS459del) potently promoted focus formation in
chick embryonic fibroblasts [21], and that both R574fs and
T576del mutations were amongst the three most potent P85a
mutants for conferring growth factor independence to Ba/F3 cells
[10].
Figure 2. Expression of mutant P85a promoted transformation
of GBM-relevant cells both in vitro and in vivo. (A) Hs683 cells co-
expressing wildtype or mutant P85a and wildtype P110a were seeded
in soft agar in triplicate. The mean colony numbers (6SD) from a
representative experiment are shown. All three mutant P85a constructs
significantly (p,0.001) promoted colony formation relative to cells
expressing wildtype P85a or untransduced cells. (B) E6/E7/hTERT-
immortalized normal human astrocytes co-expressing wildtype or
mutant P85a and wildtype P110a were injected subcutaneously in
nude mice (n = 8 injections for DKRMSNS560del subline, and n= 10
injections for all other sublines). Tumor volume measurements taken 61
days post-transplantation show that P85a mutant tumors were larger.
(C) The total penetrance for each subline upon termination of the
experiment 300 days post-injection is shown. (D) Whole cell lysates
were generated from two tumors of each subline. Western blotting
confirmed that tumors retained expression of mutant P85a, and that
tumors expressing mutant P85a demonstrated higher levels of pAKT.
Numerical values below the pAKT panel of the immunoblot represent
quantification of the relative protein level by densitometry (normalized
to AKT).
doi:10.1371/journal.pone.0049466.g002
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Although the other tested mutations of P85a did not directly
alter P110a activity in in vitro assays, it is conceivable that they may
alter PI3K pathway signaling through other mechanisms. For
example, one P85a mutant (E160fs) was recently shown to have
lost the ability to bind P110a, but still deregulated PI3K signaling
through altered binding and stabilization of PTEN [10]. Similarly,
a mutation that alters the interaction of the P110a-P85a
heterodimer with the lipid bilayer, or of P85a interactions with
tyrosine kinase receptors, would not be expected to exhibit
increased kinase activity in an in vitro setting. For example, the
KS459del mutation was shown to increase transformation of chick
embryonic fibroblasts [21] while it showed no effect on in vitro
kinase activity. Thorough mechanistic studies will therefore be
required to determine if all observed somatic mutations of PIK3R1
in GBM are transforming, and if so, by what mechanism(s) they
promote tumorigenesis.
Based on current data sets, somatic mutations of PIK3R1 appear
to be limited to a subset of tumor types. While colon cancers,
endometrial cancers, and GBM’s have been shown to contain a
high frequency of PIK3R1mutations, sequencing of more than 200
non-small cell lung cancer tumors did not identify mutations in
PIK3R1 [9]. Sequencing of numerous other tumor types has also
failed to identify a high frequency of somatic mutations of PIK3R1,
though the sample sizes in many of these studies remain too small
to preclude the existence of PIK3R1 mutations. Interestingly,
,45% of PIK3R1-mutant colon cancer specimens and ,22% of
PIK3R1-mutant endometrioid endometrial cancers also carried
mutations of PIK3CA [9,10,20]. In contrast, mutations in PIK3R1
were found to be mutually exclusive with mutations in PIK3CA in
primary GBM tumors [2,3]. These findings suggest that the overall
genetic/developmental context of a tumor dictates the mutational
spectrum that will drive tumor development and progression.
While these studies have focused on the role of PIK3R1
mutations in stimulating PI3K activity, additional studies will have
to be performed to determine whether any of these alterations
phenocopy the frequent mutations and deletions that are observed
in PTEN, or whether these independent mutations can act in
concert to promote tumor progression. The latter possibility is
supported by the common coexistence of mutations in PIK3R1 and
PTEN in endometrial cancer [10], and the ability of concurrent
mutations in Pik3ca and Pten to promote the formation of ovarian
Figure 3. Expression of mutant P85a promoted intracranial
tumor formation by primary astrocytes. (A) Scatter plot of the
number of days post-injection until neurological or physical symptoms
were observed (n = 5 mice were injected in each group). Mutant P85a
expressing cells formed more tumors with a significantly shorter latency
(p,0.001) than cells expressing wildtype P85a. (B) Representative
micrographs of hematoxylin and eosin stained tissue sections obtained
from mice after intracranial injection of E6/E7/hTERT-immortalized
normal human astrocytes co-expressing wildtype or mutant P85a and
wildtype P110a. Tumors are indicated by arrowheads, and scale bars
represent 1 mm. (C) Representative micrographs showing regions of
necrosis (N) and mitotic figures (arrowheads) in an intracranial tumor
formed by astrocytes expressing the DKRMNS560del mutant P85a.
Scale bars represent 100 mm.
doi:10.1371/journal.pone.0049466.g003
Table 1. IC50 values (mM) for treatment of Ba/F3 sublines
with MK2206.
Control IL-3
Parental 0.0232 0.0272
P85 0.0149 0.0146
DKRMNS560del 0.0018 0.0033*
R574fs 0.0026 0.0122**
T576del 0.0037 0.0115**
*p,0.05,
**p,0.0001.
doi:10.1371/journal.pone.0049466.t001
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serous adenocarcinomas in mice [22]. Alone, each of these
alterations will likely lead to the upregulation of signaling
intermediates such as AKT, but such combinatorial variation of
activating mutations may in fact have diverse consequences on
parallel signaling networks as well as on the overall state of the
cancer cell. It will thus also be necessary to determine how the
spectrum of alterations in the PI3K pathway influences the
sensitivity of these tumors to inhibitors targeting specific compo-
nents within the pathway. For example, our results suggest that
mutations in the iSH2 domain of PIK3R1 sensitize GBM cells to
the inhibition of AKT by small molecules such as MK2206.
However, it is conceivable that in the context of mutation of both
PIK3R1 and PTEN, for example, that GBM cells may be sensitive
to other inhibitors of the PI3K pathway, or of entirely independent
pathways. Given the complexity of these genetic and molecular
interactions, it may be necessary to empirically determine how the
spectrum of PI3K mutations in a GBM cell impacts its therapeutic
dependencies, with the hope of translating these findings to the
clinical situation.
In summary, we have demonstrated that beyond biochemical
activation of PI3K signaling, somatic mutations of PIK3R1 are able
to promote transformation of primary normal human astrocytes in
vivo. Taken together, these data support the contention that
mutations in P85a, and particularly those in the iSH2 domain, act
by allowing P110a to exhibit a higher basal activity level, and thus
somatic mutation of PIK3R1 provides tumors with an additional
mechanism to deregulate PI3K signaling and promote tumor
progression.
Supporting Information
Table S1 Results of sequencing the PIK3R1 and PIK3CA loci in
28 human GBM cell lines.
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